Table 1.
Effects of salmeterol/fluticasone and fluticasone propionate on inflammatory cell outcomes (fully published papers only)
| Reference | Medication | Duration | Inflammatory cell outcomes |
|---|---|---|---|
| Barnes et al 2006 | Salmeterol/fluticasone (SF) 50/500 μg (n = 55) | 13 weeks | • SF significantly reduced the absolute numbers of biopsy (CD45+) leukocytes, CD8+ cells, and CD4+ cells. |
| versus | • In biopsy SF significantly decreases cells expressing genes for TNF-α and IFN-γ. | ||
| placebo (n = 69) | • No significant CD8:CD4 ratio differences or number of CD68+ cells. | ||
| Gizycki et al 2002 | Fluticasone Propionate (FP) 500 μg bid (n = 14) | 3 month | • Compared with baseline, FP treatment had no significant effects on the total number of inflammatory cells, lymphomononuclear cells, or macrophages in the airway mucosa. |
| versus | • Compared with baseline and placebo FP did show a significant reduction in the number of mucosal mast cells. | ||
| placebo (n = 10) | • Compared with placebo the FP group had significantly more neutrophils after treatment. | ||
| Hattotuwa et al 2002 | Fluticasone propionate (FP) 500 μg bid (n = 16) | 3 month | • No significant change in CD3+, CD8+, CD45, CD45Ro+ cells, neutrophils, macrophages, mast cells and eosinophils between baseline and end treatment. |
| versus | • No significant reduction in neutrophils compared with placebo treatment. In comparison with placebo mast cells showed a 25% decrease in number in the subepithelium after FP (p = 0.04). | ||
| placebo (n = 14) | • Significant reduction in the numbers of mucosal mast cells. | ||
| • A reduction in the CD8:CD4 ratio in the epithelium and the numbers of subepithelial mast cells in the FP group. | |||
| • CD4+ cells were significantly raised in the placebo group in both epithelium and subepithelium |
Abbreviations: FP, fluticasone propionate; PF, ; SF, salmeterol/fluticasone.